|
Market Closed -
Sao Paulo
22:50:46 20/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 65.52 BRL | +1.08% |
|
+5.30% | +14.29% |
| 10-19 | Gilead Sciences, Inc. Presents New Findings From Its HIV And Antiviral Research And Development Programs At IDWeek 2026 | CI |
| 10-19 | Gilead's pill succeeds in mid-stage bowel disease trial | RE |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 194,065 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 27.44% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 215,337 | 207,685 | 200,648 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 26.98% | -3.55% | -3.39% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.6x | 19.3x | 17.8x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 13.7x | 9.66x | 7.35x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.01x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.31x | 5.9x | 5.62x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 7x | 6.32x | 5.81x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 27.1x | 11.3x | 10.7x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 65.1x | 13x | 11.7x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -409x | 14.4x | 14.5x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.24% | 6.93% | 6.91% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.297 | 3.358 | 3.077 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.11% | 2.15% | 1.97% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.431 | 8.089 | 8.804 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -96.1% | 41.5% | 34.9% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,760 | 32,885 | 34,561 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,938 | 18,367 | 18,821 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,309 | 16,012 | 17,127 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,257 | 10,268 | 10,526 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 21,272 | 13,619 | 6,583 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 156.51 | 156.51 | 156.51 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 2/1/22 A | 2/2/23 A | 2/6/24 A | 2/11/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 36.99x | 13.22x | 28x | 0.53% | 1,144B | |
| 37.96x | 6.39x | 17.99x | 2.06% | 625B | |
| 36.9x | 8.47x | 17.49x | 2.38% | 511B | |
| 21.13x | 5.1x | 12.68x | 2.57% | 377B | |
| 108.1x | 6.04x | 25.89x | 2.3% | 366B | |
| 21.5x | 5.61x | 13.79x | 2.85% | 291B | |
| 22.06x | 4.46x | 12.76x | 1.98% | 262B | |
| 27.87x | 7.15x | 12.8x | 2.3% | 237B | |
| -45.73x | 7.01x | 27.13x | 2.11% | 194B | |
| Average | 29.64x | 7.05x | 18.73x | 2.12% | 445.32B | |
| Weighted average by Cap. | 35.48x | 8.34x | 20.49x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
